Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Shapiro

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Proteomes|May 27, 2014
Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast CancerStefani N Thomas, Zhongping Liao, David Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 28, 2020
Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative StressRamon Martinez, Weiliang Huang, Ramin Samadani, et al.
Nature Communications|July 21, 2011
Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphomaBojie Dai, X Frank Zhao, Krystyna Mazan-Mamczarz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 17, 2017
Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory ActivityNirav G Shah, Mohan E Tulapurkar, Aparna Ramarathnam, et al.
The Biochemical Journal|February 20, 2015
Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRafRamin Samadani, Jun Zhang, Amanda Brophy, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2025
First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing propertiesMohan E Tulapurkar, Kari Ann Shirey, Katerina Lugkey, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-stabilizing PropertiesMohan E Tulapurkar, Kari Ann Shirey, Katerina N Lugkey, et al.
Blood|April 18, 2022
The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasmYong Zhang, Billy Truong, Shawn P Fahl, et al.
Organic & Biomolecular Chemistry|April 30, 2013
Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signalingKwan-Young Jung, Ramin Samadani, Jay Chauhan, et al.
European Journal of Medicinal Chemistry|March 18, 2016
Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoproteinMaryanna E Lanning, Wenbo Yu, Jeremy L Yap, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Proteomes|May 27, 2014
Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast CancerStefani N Thomas, Zhongping Liao, David Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 28, 2020
Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative StressRamon Martinez, Weiliang Huang, Ramin Samadani, et al.
Nature Communications|July 21, 2011
Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphomaBojie Dai, X Frank Zhao, Krystyna Mazan-Mamczarz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 17, 2017
Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory ActivityNirav G Shah, Mohan E Tulapurkar, Aparna Ramarathnam, et al.
The Biochemical Journal|February 20, 2015
Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRafRamin Samadani, Jun Zhang, Amanda Brophy, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2025
First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing propertiesMohan E Tulapurkar, Kari Ann Shirey, Katerina Lugkey, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-stabilizing PropertiesMohan E Tulapurkar, Kari Ann Shirey, Katerina N Lugkey, et al.
Blood|April 18, 2022
The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasmYong Zhang, Billy Truong, Shawn P Fahl, et al.
Organic & Biomolecular Chemistry|April 30, 2013
Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signalingKwan-Young Jung, Ramin Samadani, Jay Chauhan, et al.
European Journal of Medicinal Chemistry|March 18, 2016
Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoproteinMaryanna E Lanning, Wenbo Yu, Jeremy L Yap, et al.
Pageof 8